{"transactions":[{"id":969402,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-16T02:34:54.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":false,"shares":832453,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"All options exercised by the reporting person would have expired in March 2026 if not exercised."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":22150227,"derivative":{"exercise_price":12.68,"expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":832453},"source":{"system":"sec-edgar","filing":"0001635075-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000163507525000006/primary_doc.xml","form_type":"4"}},{"id":969401,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-16T02:34:54.000Z","date":"2025-12-12","kind":"exercise","planned":false,"acquired":false,"shares":4672724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"All options exercised by the reporting person would have expired in March 2026 if not exercised."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":22982680,"derivative":{"exercise_price":12.68,"expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":4672724},"source":{"system":"sec-edgar","filing":"0001635075-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000163507525000006/primary_doc.xml","form_type":"4"}},{"id":969400,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-16T02:34:54.000Z","date":"2025-12-11","kind":"exercise","planned":false,"acquired":false,"shares":1869691,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"All options exercised by the reporting person would have expired in March 2026 if not exercised."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":27655404,"derivative":{"exercise_price":12.68,"expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":1869691},"source":{"system":"sec-edgar","filing":"0001635075-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000163507525000006/primary_doc.xml","form_type":"4"}},{"id":969399,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-12-16T02:34:54.000Z","date":"2025-12-15","kind":"other","planned":false,"acquired":false,"shares":478708,"price":22.05,"value":10555511.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of options previously granted to the reporting person in order to satisfy the exercise price applicable to such options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.88 to $22.49, inclusive."}],"balance_after":33653755,"source":{"system":"sec-edgar","filing":"0001635075-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000163507525000006/primary_doc.xml","form_type":"4"}},{"id":969398,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-12-16T02:34:54.000Z","date":"2025-12-15","kind":"sale","planned":false,"acquired":false,"shares":353745,"price":22.05,"value":7800077.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.88 to $22.49, inclusive."}],"balance_after":34132463,"source":{"system":"sec-edgar","filing":"0001635075-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000163507525000006/primary_doc.xml","form_type":"4"}},{"id":969397,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-12-16T02:34:54.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":true,"shares":832453,"price":12.68,"value":10555504.04,"ownership":{"direct":true},"balance_after":34486208,"source":{"system":"sec-edgar","filing":"0001635075-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000163507525000006/primary_doc.xml","form_type":"4"}},{"id":969396,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-12-16T02:34:54.000Z","date":"2025-12-12","kind":"other","planned":false,"acquired":false,"shares":2696866,"price":21.96,"value":59223177.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of options previously granted to the reporting person in order to satisfy the exercise price applicable to such options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.65 to $22.13, inclusive."}],"balance_after":33653755,"source":{"system":"sec-edgar","filing":"0001635075-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000163507525000006/primary_doc.xml","form_type":"4"}},{"id":969395,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-12-16T02:34:54.000Z","date":"2025-12-12","kind":"sale","planned":false,"acquired":false,"shares":1975858,"price":21.96,"value":43389841.68,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.65 to $22.13, inclusive."}],"balance_after":36350621,"source":{"system":"sec-edgar","filing":"0001635075-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000163507525000006/primary_doc.xml","form_type":"4"}},{"id":969394,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-12-16T02:34:54.000Z","date":"2025-12-12","kind":"exercise","planned":false,"acquired":true,"shares":4672724,"price":12.68,"value":59250140.32,"ownership":{"direct":true},"balance_after":38326479,"source":{"system":"sec-edgar","filing":"0001635075-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000163507525000006/primary_doc.xml","form_type":"4"}},{"id":969393,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-12-16T02:34:54.000Z","date":"2025-12-11","kind":"other","planned":false,"acquired":false,"shares":1095550,"price":21.64,"value":23707702.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of options previously granted to the reporting person in order to satisfy the exercise price applicable to such options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.35 to $22.05, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4."}],"balance_after":33653755,"source":{"system":"sec-edgar","filing":"0001635075-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000163507525000006/primary_doc.xml","form_type":"4"}},{"id":969392,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-12-16T02:34:54.000Z","date":"2025-12-11","kind":"sale","planned":false,"acquired":false,"shares":774142,"price":21.64,"value":16752432.88,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.35 to $22.05, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4."}],"balance_after":34749305,"source":{"system":"sec-edgar","filing":"0001635075-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000163507525000006/primary_doc.xml","form_type":"4"}},{"id":969391,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-12-16T02:34:54.000Z","date":"2025-12-11","kind":"exercise","planned":false,"acquired":true,"shares":1869691,"price":12.68,"value":23707681.88,"ownership":{"direct":true},"balance_after":35523447,"source":{"system":"sec-edgar","filing":"0001635075-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000163507525000006/primary_doc.xml","form_type":"4"}},{"id":997710,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-11-17T22:52:04.000Z","date":"2025-11-17","kind":"sale","planned":false,"acquired":false,"shares":539650,"price":20.51,"value":11068221.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.72, inclusive."}],"balance_after":33653756,"source":{"system":"sec-edgar","filing":"0001635075-25-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000163507525000005/primary_doc.xml","form_type":"4"}},{"id":997709,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-11-17T22:52:04.000Z","date":"2025-11-14","kind":"sale","planned":false,"acquired":false,"shares":1027670,"price":20.33,"value":20892531.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $21.11, inclusive."}],"balance_after":34193406,"source":{"system":"sec-edgar","filing":"0001635075-25-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000163507525000005/primary_doc.xml","form_type":"4"}},{"id":997708,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-11-17T22:52:04.000Z","date":"2025-11-13","kind":"sale","planned":false,"acquired":false,"shares":287283,"price":20.81,"value":5978359.23,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.54 to $21.08, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4."}],"balance_after":35221076,"source":{"system":"sec-edgar","filing":"0001635075-25-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000163507525000005/primary_doc.xml","form_type":"4"}},{"id":1004866,"issuer":{"id":4444,"kind":"organization","name":"Strive, Inc.","symbol":"ASST"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Variable Rate Series A Perpetual Preferred Stock","published_at":"2025-11-07T23:50:59.000Z","date":"2025-11-05","kind":"purchase","planned":false,"acquired":true,"shares":15625,"price":80,"value":1250000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares purchased in connection with the underwritten public offering of Variable Rate Series A Perpetual Preferred Stock, $0.001 par value per share, of the Issuer (the \"SATA Stock\"). The shares of SATA Stock were purchased at the public offering price of $80.00 per share."}],"balance_after":15625,"source":{"system":"sec-edgar","filing":"0000950103-25-014486","document":"dp237138_4-vivek.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000095010325014486/dp237138_4-vivek.xml","form_type":"4"}},{"id":1046801,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-09-05T21:01:38.000Z","date":"2025-09-05","kind":"sale","planned":false,"acquired":false,"shares":385816,"price":12.96,"value":5000175.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.90 to $13.04, inclusive."}],"balance_after":35508359,"source":{"system":"sec-edgar","filing":"0002007997-25-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000200799725000007/primary_doc.xml","form_type":"4"}},{"id":1046800,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-09-05T21:01:38.000Z","date":"2025-09-04","kind":"sale","planned":false,"acquired":false,"shares":194933,"price":12.92,"value":2518534.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive."}],"balance_after":35894175,"source":{"system":"sec-edgar","filing":"0002007997-25-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000200799725000007/primary_doc.xml","form_type":"4"}},{"id":1046799,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-09-05T21:01:38.000Z","date":"2025-09-03","kind":"sale","planned":false,"acquired":false,"shares":1195000,"price":12.5,"value":14937500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.39 to $12.71, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4."}],"balance_after":36089108,"source":{"system":"sec-edgar","filing":"0002007997-25-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000200799725000007/primary_doc.xml","form_type":"4"}},{"id":1103743,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-06-23T15:35:06.000Z","date":"2025-06-20","kind":"sale","planned":false,"acquired":false,"shares":577007,"price":11.46,"value":6612500.22,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.45 to $11.54, inclusive."}],"balance_after":37284108,"source":{"system":"sec-edgar","filing":"0002007997-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000200799725000006/primary_doc.xml","form_type":"4"}},{"id":1103742,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-06-23T15:35:06.000Z","date":"2025-06-18","kind":"sale","planned":false,"acquired":false,"shares":565266,"price":11.45,"value":6472295.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.41 to $11.53, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."}],"balance_after":37861115,"source":{"system":"sec-edgar","filing":"0002007997-25-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000200799725000006/primary_doc.xml","form_type":"4"}},{"id":1119595,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-06-06T21:49:26.000Z","date":"2025-06-06","kind":"sale","planned":false,"acquired":false,"shares":200800,"price":11.19,"value":2246952.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.16 to $11.31, inclusive."}],"balance_after":38426381,"source":{"system":"sec-edgar","filing":"0002007997-25-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000200799725000004/primary_doc.xml","form_type":"4"}},{"id":1119594,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-06-06T21:49:26.000Z","date":"2025-06-04","kind":"sale","planned":false,"acquired":false,"shares":547430,"price":11.34,"value":6207856.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.25 to $11.47, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4"}],"balance_after":38627181,"source":{"system":"sec-edgar","filing":"0002007997-25-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000200799725000004/primary_doc.xml","form_type":"4"}},{"id":1155049,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-05-09T00:51:50.000Z","date":"2025-05-07","kind":"sale","planned":false,"acquired":false,"shares":625000,"price":11.18,"value":6987500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.10 to $11.26, inclusive."}],"balance_after":39174611,"source":{"system":"sec-edgar","filing":"0001214659-25-007221","document":"marketforms-69403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000121465925007221/marketforms-69403.xml","form_type":"4"}},{"id":1155048,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-05-09T00:51:50.000Z","date":"2025-05-06","kind":"sale","planned":false,"acquired":false,"shares":273959,"price":11.47,"value":3142309.73,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.45 to $11.52, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4"}],"balance_after":39799611,"source":{"system":"sec-edgar","filing":"0001214659-25-007221","document":"marketforms-69403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000121465925007221/marketforms-69403.xml","form_type":"4"}},{"id":1294427,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-01-27T16:40:22.000Z","date":"2025-01-23","kind":"gift","planned":false,"acquired":true,"shares":13357857,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Spousal"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents the quantity of shares held indirectly only."}],"balance_after":13357857,"source":{"system":"sec-edgar","filing":"0002007997-25-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000200799725000001/primary_doc.xml","form_type":"4"}},{"id":1294426,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-01-27T16:40:22.000Z","date":"2025-01-23","kind":"gift","planned":false,"acquired":false,"shares":13357857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction represents a transfer of Common Shares for estate planning purposes intra-household."}],"balance_after":40073570,"source":{"system":"sec-edgar","filing":"0002007997-25-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000200799725000001/primary_doc.xml","form_type":"4"}},{"id":1692412,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-01-03T21:56:57.000Z","date":"2024-01-02","kind":"sale","planned":false,"acquired":false,"shares":3000000,"price":11.05,"value":33150000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock covering Common Shares that is fully vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects an award of restricted stock covering Common Shares that is fully vested."}],"balance_after":51929426,"source":{"system":"sec-edgar","filing":"0001420506-24-000003","document":"doc4_1100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000142050624000003/doc4_1100.xml","form_type":"4"}},{"id":1697933,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Capped Value Appreciation Rights","published_at":"2023-12-30T02:00:28.000Z","date":"2023-12-27","kind":"exercise","planned":true,"acquired":false,"shares":251538,"price":11.5,"value":2892687.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On December 27, 2023, the hurdle price applicable to 251,538 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 1,737 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"On December 27, 2023, the hurdle price applicable to 251,538 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 1,737 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On December 27, 2023, the hurdle price applicable to 251,538 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 1,737 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 27, 2023, the hurdle price applicable to 251,538 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 1,737 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"On December 27, 2023, the hurdle price applicable to 251,538 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 1,737 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."}],"balance_after":11570769,"derivative":{"expiration_date":"2026-03-31","underlying":"Common Shares","underlying_shares":1737},"source":{"system":"sec-edgar","filing":"0001140361-23-060295","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123060295/form4.xml","form_type":"4"}},{"id":1697932,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Capped Value Appreciation Rights","published_at":"2023-12-30T02:00:28.000Z","date":"2023-12-27","kind":"exercise","planned":true,"acquired":false,"shares":611393,"price":6.4,"value":3912915.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On December 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 611,393 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 273,490 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"On December 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 611,393 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 273,490 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 611,393 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 273,490 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On December 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 611,393 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 273,490 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On December 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 611,393 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 273,490 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."}],"balance_after":7132921,"derivative":{"expiration_date":"2026-03-31","underlying":"Common Shares","underlying_shares":273490},"source":{"system":"sec-edgar","filing":"0001140361-23-060295","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123060295/form4.xml","form_type":"4"}},{"id":1697931,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2023-12-30T02:00:28.000Z","date":"2023-12-27","kind":"tax_withholding","planned":true,"acquired":false,"shares":133911,"price":11.58,"value":1550689.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the \"net settlement\" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes an award of restricted stock covering Common Shares that is fully vested."}],"balance_after":54929426,"source":{"system":"sec-edgar","filing":"0001140361-23-060295","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123060295/form4.xml","form_type":"4"}},{"id":1697930,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2023-12-30T02:00:28.000Z","date":"2023-12-27","kind":"exercise","planned":true,"acquired":true,"shares":275227,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 611,393 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 273,490 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 27, 2023, the hurdle price applicable to 251,538 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 1,737 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 611,393 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 273,490 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On December 27, 2023, the hurdle price applicable to 251,538 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 1,737 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes an award of restricted stock covering Common Shares that is fully vested."}],"balance_after":55063337,"source":{"system":"sec-edgar","filing":"0001140361-23-060295","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123060295/form4.xml","form_type":"4"}},{"id":1771506,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Capped Value Appreciation Rights","published_at":"2023-09-30T01:30:34.000Z","date":"2023-09-27","kind":"exercise","planned":false,"acquired":false,"shares":251539,"price":11.5,"value":2892698.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On September 27, 2023, the hurdle price applicable to 251,539 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 22,503 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"On September 27, 2023, the hurdle price applicable to 251,539 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 22,503 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On September 27, 2023, the hurdle price applicable to 251,539 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 22,503 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On September 27, 2023, the hurdle price applicable to 251,539 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 22,503 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"On September 27, 2023, the hurdle price applicable to 251,539 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 22,503 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."}],"balance_after":11822307,"derivative":{"expiration_date":"2026-03-31","underlying":"Common Shares","underlying_shares":22503},"source":{"system":"sec-edgar","filing":"0001140361-23-046107","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123046107/form4.xml","form_type":"4"}},{"id":1771505,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Capped Value Appreciation Rights","published_at":"2023-09-30T01:30:34.000Z","date":"2023-09-27","kind":"exercise","planned":false,"acquired":false,"shares":203798,"price":6.4,"value":1304307.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On September 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 203,798 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 97,031 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"On September 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 203,798 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 97,031 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 203,798 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 97,031 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On September 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 203,798 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 97,031 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On September 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 203,798 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 97,031 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."}],"balance_after":7744314,"derivative":{"expiration_date":"2026-03-31","underlying":"Common Shares","underlying_shares":97031},"source":{"system":"sec-edgar","filing":"0001140361-23-046107","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123046107/form4.xml","form_type":"4"}},{"id":1771504,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2023-09-30T01:30:34.000Z","date":"2023-09-28","kind":"other","planned":false,"acquired":false,"shares":61947,"price":12.67,"value":784868.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs. This sale was effected pursuant to the issuer's \"sell to cover\" policy and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in this column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $13.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes an award of restricted stock covering Common Shares that is fully vested."}],"balance_after":54788110,"source":{"system":"sec-edgar","filing":"0001140361-23-046107","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123046107/form4.xml","form_type":"4"}},{"id":1771503,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2023-09-30T01:30:34.000Z","date":"2023-09-27","kind":"exercise","planned":false,"acquired":true,"shares":119534,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 203,798 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 97,031 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On September 27, 2023, the hurdle price applicable to 251,539 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 22,503 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 203,798 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 97,031 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On September 27, 2023, the hurdle price applicable to 251,539 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 22,503 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes an award of restricted stock covering Common Shares that is fully vested."}],"balance_after":54850057,"source":{"system":"sec-edgar","filing":"0001140361-23-046107","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123046107/form4.xml","form_type":"4"}},{"id":1794197,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Capped Value Appreciation Rights","published_at":"2023-08-30T01:31:26.000Z","date":"2023-08-27","kind":"exercise","planned":false,"acquired":false,"shares":203798,"price":6.4,"value":1304307.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the conversion of 203,798 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On August 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 86,714 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on August 25, 2023."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the conversion of 203,798 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On August 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 86,714 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on August 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of 203,798 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On August 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 86,714 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on August 25, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the conversion of 203,798 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On August 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 86,714 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on August 25, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects the conversion of 203,798 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On August 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 86,714 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on August 25, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."}],"balance_after":7948112,"derivative":{"expiration_date":"2026-03-31","underlying":"Common Shares","underlying_shares":86714},"source":{"system":"sec-edgar","filing":"0001140361-23-041707","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123041707/form4.xml","form_type":"4"}},{"id":1794196,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2023-08-30T01:31:26.000Z","date":"2023-08-28","kind":"other","planned":false,"acquired":false,"shares":47692,"price":11.25,"value":536535.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs. This sale was effected pursuant to the issuer's \"sell to cover\" policy and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in this column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.08 to $11.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes an award of restricted stock covering Common Shares that is fully vested."}],"balance_after":54730523,"source":{"system":"sec-edgar","filing":"0001140361-23-041707","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123041707/form4.xml","form_type":"4"}},{"id":1794195,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2023-08-30T01:31:26.000Z","date":"2023-08-27","kind":"exercise","planned":false,"acquired":true,"shares":86714,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the conversion of 203,798 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On August 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 86,714 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on August 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of 203,798 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On August 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 86,714 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on August 25, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes an award of restricted stock covering Common Shares that is fully vested."}],"balance_after":54778215,"source":{"system":"sec-edgar","filing":"0001140361-23-041707","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123041707/form4.xml","form_type":"4"}},{"id":1819145,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Capped Value Appreciation Rights","published_at":"2023-08-01T10:13:35.000Z","date":"2023-07-27","kind":"exercise","planned":false,"acquired":false,"shares":407595,"price":6.4,"value":2608608.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the conversion of 407,595 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On July 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 166,057 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on July 27, 2023."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the conversion of 407,595 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On July 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 166,057 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on July 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of 407,595 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On July 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 166,057 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on July 27, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the conversion of 407,595 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On July 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 166,057 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on July 27, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects the conversion of 407,595 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On July 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 166,057 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on July 27, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."}],"balance_after":8151910,"derivative":{"expiration_date":"2026-03-31","underlying":"Common Shares","underlying_shares":166057},"source":{"system":"sec-edgar","filing":"0001140361-23-037146","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123037146/form4.xml","form_type":"4"}},{"id":1819144,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2023-08-01T10:13:35.000Z","date":"2023-07-31","kind":"other","planned":false,"acquired":false,"shares":76023,"price":11.43,"value":868942.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs. This sale was effected pursuant to the issuer's \"sell to cover\" policy and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in this column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.77 to $11.97, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"5.Includes an award of restricted stock covering Common Shares that is fully vested."}],"balance_after":54691501,"source":{"system":"sec-edgar","filing":"0001140361-23-037146","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123037146/form4.xml","form_type":"4"}},{"id":1819143,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2023-08-01T10:13:35.000Z","date":"2023-07-27","kind":"exercise","planned":false,"acquired":true,"shares":166057,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the conversion of 407,595 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On July 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 166,057 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on July 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of 407,595 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On July 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 166,057 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on July 27, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"5.Includes an award of restricted stock covering Common Shares that is fully vested."}],"balance_after":54767524,"source":{"system":"sec-edgar","filing":"0001140361-23-037146","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123037146/form4.xml","form_type":"4"}},{"id":1873324,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Capped Value Appreciation Rights","published_at":"2023-06-01T01:30:35.000Z","date":"2023-05-27","kind":"exercise","planned":false,"acquired":false,"shares":1222787,"price":6.4,"value":7825836.8,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the conversion of 1,222,787 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On May 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 382,203 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on May 26, 2023."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the conversion of 1,222,787 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On May 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 382,203 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on May 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of 1,222,787 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On May 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 382,203 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on May 26, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the conversion of 1,222,787 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On May 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 382,203 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on May 26, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects the conversion of 1,222,787 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On May 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 382,203 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on May 26, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."}],"balance_after":8559505,"derivative":{"expiration_date":"2026-03-31","underlying":"Common Shares","underlying_shares":382203},"source":{"system":"sec-edgar","filing":"0001140361-23-027615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123027615/form4.xml","form_type":"4"}},{"id":1873323,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2023-06-01T01:30:35.000Z","date":"2023-05-31","kind":"other","planned":false,"acquired":false,"shares":189947,"price":9.09,"value":1726618.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs. This sale was effected pursuant to the issuer's \"sell to cover\" policy and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in this column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.95 to $9.31, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes an award of restricted stock covering Common Shares that is fully vested."}],"balance_after":54601467,"source":{"system":"sec-edgar","filing":"0001140361-23-027615","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123027615/form4.xml","form_type":"4"}},{"id":1873322,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2023-06-01T01:30:35.000Z","date":"2023-05-27","kind":"exercise","planned":false,"acquired":true,"shares":382203,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the conversion of 1,222,787 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On May 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 382,203 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on May 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of 1,222,787 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On May 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 382,203 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on May 26, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes an award of restricted stock covering Common Shares that is fully vested."}],"balance_after":54791414,"source":{"system":"sec-edgar","filing":"0001140361-23-027615","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123027615/form4.xml","form_type":"4"}},{"id":1999827,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-02-22T22:04:06.000Z","date":"2023-02-22","kind":"sale","acquired":false,"shares":4000000,"price":7.95,"value":31800000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person does not expect to sell additional shares of the Issuer for the foreseeable future."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects an award of restricted stock covering Common Shares that is fully vested."}],"balance_after":54409211,"source":{"system":"sec-edgar","filing":"0001140361-23-008049","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036123008049/form4.xml","form_type":"4"}},{"id":3885073,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-06-22T20:24:00.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":6.75,"exercise_date":"2018-06-19","expiration_date":"2028-06-19","underlying":"Common Shares","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001140361-18-029605","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000114036118029605/doc1.xml","form_type":"4"}},{"id":4273530,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":71553,"kind":"person","name":"Ramaswamy Vivek","position":1,"cik":"0001635075","reported_name":"Ramaswamy Vivek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-23T20:02:10.000Z","date":"2017-06-21","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":22000,"derivative":{"exercise_price":3.55,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-17-041628","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635075/000120919117041628/doc4.xml","form_type":"4"}}]}